Перейти к главному меню навигации Перейти к основному контенту Перейти к нижнему колонтитулу сайта

Том 3 № 12 (2024)
Science and innovation in the education system

Статьи

ASSESSMENT OF INDICATORS OF CYTOPENIC SYNDROME IN PATIENTS DIAGNOSED WITH LIVER CIRRHOSIS OF VIRUS ETIOLOGY

Опубликован 2024-10-08

  • Kurbonova Z.Ch.
    • ,
  • Anvarov J.A.
    • ,
  • Shodiyeva G.E.
    • ,
  • Adilov A.A.
    • ,
  • Sherkulov B.B.

Kurbonova Z.Ch.
Tashkent Medical Academy, Tashkent

Anvarov J.A.
Tashkent Medical Academy, Tashkent

Shodiyeva G.E.
Tashkent Medical Academy, Tashkent

Adilov A.A.
Tashkent Medical Academy, Tashkent

Sherkulov B.B.
Tashkent Medical Academy, Tashkent

Аннотация

In the world, special attention is being paid to scientific research aimed at identifying changes in the general blood analysis in liver cirrhosis of viral etiology, as well as the characteristics of cytopenic syndrome and improving measures to develop these changes. In this regard, the study of the etiological factors of liver cirrhosis, that is, the study of the molecular genetic characteristics of the hepatitis B virus (HBV) and hepatitis C virus (HCV), the identification of the pathogenetic development of the disease in patients with liver cirrhosis, the assessment of the level of features of cytopenic syndrome in these patients and their study of various stages of liver diseases and their relationship with etiology, early diagnosis of these changes and improvement of treatment requires implementation of a number of tasks, and conducting research in this direction is of particular importance.

PDF

Библиографические ссылки

  1. Rowe IA. Lessons from Epidemiology: The Burden of Liver Disease. Dig Dis. 2017;35(4):304-9.
  2. Mokdad AA, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine. 2014;12:145.
  3. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies.J Hepatol. 2018;69(3):718-35.
  4. Global status report on alcohol and health 2018. WHO, 2018.
  5. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60.
  6. Garcia-Tsao G, Abraldes JG, Berzigotti A. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-35.
  7. The European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. – Direct text // J Hepatol. – 2018. – № 69 (2). – Р. 406 – 460.
  8. Suk, K. T. Gut microbiota: Novel therapeutic target for nonalcoholic fatty liver disease. – Direct text / K. T. Suk, D. J. Kim // Expert Rev. Gastroenterol. Hepatol. – 2019. – № 13. – Р. 193 – 204.